Extended antiviral therapy may shield transplant patients from dangerous virus
NCT ID NCT06812598
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving letermovir for a longer time (up to 28 weeks) can prevent cytomegalovirus (CMV) infection in Chinese adults who have a high risk of reactivation after a stem cell transplant. Participants must be at least 18, have had a stem cell transplant, and have certain risk factors like a mismatched donor or cord blood. The goal is to see if extended treatment reduces CMV-related complications without increasing side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hematology Department, The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells predict herpesvirus danger in transplant patients?
- Can specially grown immune cells from donors beat viruses that won't go away?
- Blood test could tailor CMV prevention after stem cell transplants
- Immune cell levels may predict who will develop severe CMV after transplant
- Lab-Grown immune cells take aim at Life-Threatening viruses in vulnerable patients
- Hidden immune fire: could CMV or autoimmunity be fueling HIV-Related inflammation?